Get Stock Quote Here Ligand Pharmaceuticals (LGND) is a biopharmaceutical company based out of La Jolla, California that develops programs through a portfolio of assorted strategies and properties in the pharmaceutical industry. Ligand Pharmaceuticals, originally called Progenx, was founded in September 1987 by Brook Byers. The company's headquarters are in La Jolla, California. In January 2007, John Higgins became the new CEO of Ligand and the business was stripped down from 66 employees to 18. When John Higgins became CEO of Ligand Pharmaceuticals, Daniel Loeb of Third Point Management bought into the biotech firm to cut its losses and grow revenue. Loeb invested $50 million, increased the company’s profit to $250 million, and brought back $68 million in stocks. The company has a market cap of $1.65 billion.
Looks somewhat enticing...looks too good to be true? 5/4/2016 ER getting into more detail... So the real EPS is 26 cents rather than 97 cents for this quarter. The P/E (and PEG) looks great, but that was back when earnings were $12.
Ligand Pharmaceuticals Q3 EPS $1.58 Beats $1.04 Estimate, Sales $64.83M Beat $55.65M Estimate 4:40 pm ET November 9, 2021 (Benzinga) Print Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.58 per share which beat the analyst consensus estimate of $1.04 by 51.92 percent. This is a 51.92 percent increase over earnings of $1.04 per share from the same period last year. The company reported quarterly sales of $64.83 million which beat the analyst consensus estimate of $55.65 million by 16.50 percent. This is a 54.93 percent increase over sales of $41.85 million the same period last year. © 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
